Tag Archives: BIO Investor Forum

Locus Pharmaceuticals and Novartis enter into research collaboration

Locus Pharmaceuticals has entered into a discovery research collaboration with Novartis. Locus will collaborate with Novartis to discover novel chemotypes on targets of interest to Novartis’ select therapeutic areas.

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: ,

UsiRNA reduces tumor growth in vivo

MDRNA, Inc. (NASDAQ: MRNA) presented new in vivo data showing continued progress in the advancement of the Company’s oncology program. J. Michael French, President and CEO, reported that MDRNA’s UsiRNAs, delivered by the Company’s DiLA2 platform, down-regulated a previously “non-druggable” target with subsequent reductions in tumor growth in models of liver and bladder cancer via both systemic and local delivery.  Read the release.

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: ,

Medicago awarded U.S. Army contract

Medicago Inc. (TSX-V: MDG) has been awarded a proof of concept contract by the U.S. Army Research, Development and Engineering Command laboratory specifically the Edgewood Chemical Biological Center (“ECBC”) Research & Technology Directorate. Medicago will work with ECBC to investigate the affordable production of industrial enzymes in the field of biofuels. This new project builds on Medicago’s proprietary plant-based manufacturing platform and its potential for applications beyond the biological drug market. Read the release.

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: ,

Novavax gets NIH grant

Novavax, Inc. (NASDAQ:NVAX) has received a Small Business and Innovation Research grant from the National Institute of Allergy and Infectious Diseases. The grant will support a segment of the Company’s preclinical research program for the respiratory syncytial virus (RSV) particle-based vaccine. As previously announced, Novavax has an RSV vaccine candidate in preclinical development, which is directed against a protein on the surface of the virus, the “F” or “fusion” protein. The grant, valued at approximately Read More >

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: ,

Canadian patent strengthens IP for Allon’s 2nd technology platform

Allon Therapeutics Inc. (TSX: NPC), announced today that the intellectual property underlying its activity-dependent neurotrophic factor (ADNF) technology platform has been strengthened by the issuance of a Canadian patent covering the chemical composition of the Company’s preclinical-stage peptide AL-209 and its use in protecting against Alzheimer’s disease and other degenerative diseases. The Company said AL-209 has demonstrated highly potent neuroprotective activity in preclinical studies where it has been shown to block the effect of toxic Read More >

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: ,